{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-174458","form_type":"8-K","ticker":"SLNO","cik":"0001484565","company_name":"SOLENO THERAPEUTICS INC","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.087869+00:00","generated_at":"2026-05-17T19:10:36.962197+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Soleno Q2 2025: $32.7M product revenue from VYKAT XR launch; net loss $4.7M","bullets":["Product revenue, net $32.7M for Q2 2025, first quarter with VYKAT XR sales (launched April 14).","Net loss $(4.7)M or ($0.09) per share vs. $(21.9)M ($0.57) in Q2 2024.","Cash, equivalents and marketable securities $293.8M at June 30; subsequent $230M equity offering in July.","Launch metrics: 646 patient start forms, 295 unique prescribers, >100M lives covered by end of Q2.","MAA for DCCR submitted to EMA; contingent consideration liability for sales milestones estimated at $18.9M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-174458","json":"https://secwatch.observer/filing/0001193125-25-174458.json","markdown":"https://secwatch.observer/filing/0001193125-25-174458.md","text":"https://secwatch.observer/filing/0001193125-25-174458.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1484565/000119312525174458/0001193125-25-174458-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1484565/000119312525174458/d88313d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T19:10:36.962197+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}